By Mill Chart
Last update: Mar 20, 2024
Discover MERCK & CO. INC. (NYSE:MRK)—an undervalued stock our stock screener has picked out. NYSE:MRK demonstrates solid fundamentals, including health and profitability, all while staying attractively priced. Let's explore the details.
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NYSE:MRK has received a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:MRK, the assigned 8 is noteworthy for profitability:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NYSE:MRK scores a 5 out of 10:
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NYSE:MRK has achieved a 4 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
For an up to date full fundamental analysis you can check the fundamental report of MRK
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
MERCK & CO. INC.
NYSE:MRK (4/19/2024, 10:32:09 AM)
125.22
-0.01 (-0.01%)
/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Although the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop.
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Being able to stop a drug's unwanted effects could lead to a larger market share.
There's a new reason to believe that their joint projects are going well.
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.